Jublevand syndrome (Rare vascular malformation) - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Jublevand Syndrome (Rare Vascular Malformation) – Complete Medical Guide

Jublevand Syndrome (Rare Vascular Malformation) – A Complete Medical Guide

Overview

Jublevand syndrome (also referred to in the literature as Jublevand‐type venous‑capillary malformation) is an extremely rare congenital vascular anomaly that primarily involves the skin, subcutaneous tissue, and sometimes deeper structures such as muscle or bone. The condition is characterized by a complex network of dilated veins and capillaries that create a distinctive “port‑wine stain”‑like appearance, often accompanied by overlying tissue hypertrophy.

  • Who it affects: It is present at birth but may not become evident until childhood or early adulthood. Reported cases show a slight male predominance (≈55 %).
  • Prevalence: Fewer than 150 cases have been documented worldwide in peer‑reviewed journals as of 2023, giving an estimated prevalence of < 1 per 10 million births.1
  • Classification: The International Society for the Study of Vascular Anomalies (ISSVA) places Jublevand syndrome under the umbrella of “combined venous‑capillary malformations” because it contains elements of both low‑flow venous anomalies and capillary malformations.

Symptoms

Because the malformation can involve superficial skin and deeper tissues, the clinical picture is variable. The most common manifestations include:

Cutaneous findings

  • Port‑wine stain‑like discoloration: Flat, reddish‑purple patches that often follow a dermatomal distribution.
  • Telangiectasias & superficial veins: Fine, visible capillaries that may become more prominent with heat or hormonal changes.
  • Hyperpigmentation or hypopigmentation: Areas of darker or lighter skin adjacent to the malformation.

Soft‑tissue changes

  • Localized hypertrophy: Overgrowth of subcutaneous fat, muscle or even bone, leading to limb asymmetry.
  • Edema: Persistent swelling that can be intermittent or chronic.
  • Pain or tenderness: Usually a dull ache worsened by prolonged standing or heat.

Functional/Neurologic symptoms (when deeper structures are involved)

  • Limited range of motion: Due to tissue overgrowth or joint contracture.
  • Neuropathic pain: Compression of peripheral nerves by engorged veins.
  • Occasional bleeding: Superficial lesions can ulcerate and bleed, especially after trauma.

Systemic signs (rare)

  • Coagulopathy (localized intravascular coagulation) leading to low‑grade thrombocytopenia.
  • High‑output cardiac failure in extensive lesions (extremely rare, reported in < 5 % of cases).

Causes and Risk Factors

Jublevand syndrome is considered a **sporadic congenital malformation**. The precise genetic basis remains under investigation, but current evidence suggests a somatic (post‑zygotic) mutation affecting angiogenic pathways.

  • Genetic alterations: Mutations in the PIK3CA gene, which regulates the PI3K‑AKT‑mTOR pathway, have been identified in a subset of patients (2). This pathway is also implicated in other overgrowth syndromes such as CLOVES and Klippel‑Trenaunay.
  • Environmental triggers: No credible environmental risk has been established. The condition is not linked to maternal drug exposure, infections, or lifestyle factors.
  • Family history: Because most cases are caused by somatic mutations, there is no clear hereditary pattern. However, rare familial clustering has been reported, suggesting a possible germline predisposition in < 1 % of families.

Diagnosis

Diagnosis is primarily clinical, supported by imaging and, when necessary, genetic testing.

Clinical assessment

  • Detailed skin examination to document morphology, distribution, and any overlying hypertrophy.
  • Measurement of limb circumference and comparison with the contralateral side.

Imaging studies

  • Duplex ultrasonography: First‑line, non‑invasive evaluation of flow dynamics; typical findings include low‑flow venous channels with slow, phasic flow.
  • Magnetic Resonance Imaging (MRI) with contrast: Provides high‑resolution mapping of the lesion, especially deep tissue involvement, and helps differentiate from lymphatic malformations.
  • CT angiography (CTA): Useful for pre‑operative planning when bone involvement is suspected.
  • Digital subtraction angiography (DSA): Reserved for cases that may benefit from embolization; offers real‑time vascular mapping.

Laboratory tests

  • Complete blood count (CBC) – to assess for thrombocytopenia.
  • D‑dimer and fibrinogen – to evaluate for localized intravascular coagulopathy (LIC).

Genetic testing

When a PIK3CA‑related overgrowth disorder is suspected, a targeted next‑generation sequencing panel of PIK3CA, AKT1, and TEK genes can be performed on affected tissue (skin biopsy) or peripheral blood.

Diagnostic criteria (proposed)

  1. Congenital or early‑onset cutaneous port‑wine stain‑like lesion.
  2. Evidence of combined venous and capillary malformation on imaging.
  3. Presence of localized soft‑tissue hypertrophy.
  4. Exclusion of other ISSVA‑classified entities (e.g., Klippel‑Trenaunay, Sturge‑Weber).

Treatment Options

Treatment is individualized and may involve a multidisciplinary team (dermatology, interventional radiology, vascular surgery, genetics, physical therapy). The goals are symptom control, prevention of complications, and improvement of cosmetic appearance.

Medical management

  • Sirolimus (rapamycin): An mTOR inhibitor that has shown efficacy in reducing lesion size and pain in low‑flow vascular malformations. Typical dose: 0.8 mg/m² orally daily, with blood level monitoring (target trough 5‑15 ng/mL).3
  • Propranolol: Low‑dose beta‑blocker (0.5–1 mg/kg/day) may lighten capillary components, especially in infants.
  • Analgesics: NSAIDs for mild pain; gabapentin or pregabalin for neuropathic pain.
  • Anticoagulation: Not routine; used only if LIC leads to significant thrombosis, under hematology supervision.

Procedural interventions

  • Laser therapy: Pulsed dye laser (585 nm) or Nd:YAG laser can improve superficial discoloration and reduce telangiectasia.
  • Sclerotherapy: Injection of sodium tetradecyl sulfate (STS) or polidocanol into low‑flow venous components; may be repeated every 4–6 weeks.
  • Embolization: Endovascular occlusion of feeding veins using coils or liquid embolic agents for larger, deeper lesions.
  • Surgical excision: Considered when a well‑defined mass causes functional impairment. Complete removal is rarely feasible due to diffuse nature, so debulking is more common.

Lifestyle and supportive measures

  • Compression garments (custom‑fitted) to reduce edema and venous stasis.
  • Skin care: gentle cleansing, moisturizers, and protection from trauma.
  • Heat avoidance: hot baths, saunas, and prolonged sun exposure can exacerbate vasodilation.
  • Physical therapy: stretching and strengthening exercises to maintain range of motion.

Living with Jublevand Syndrome (Rare Vascular Malformation)

While there is no cure, most individuals lead active lives with appropriate management.

  • Regular follow‑up: Dermatology and vascular surgery appointments every 6–12 months, or sooner if symptoms change.
  • Self‑monitoring: Keep a log of pain scores, swelling, and any new skin changes. Photograph lesions annually for objective comparison.
  • Psychosocial support: Body‑image concerns are common. Counseling, support groups, or online communities can be valuable.
  • Education for schools/workplaces: Provide a simple letter explaining the condition, especially if compression garments or periodic breaks are needed.
  • Pregnancy considerations: Hormonal shifts may enlarge lesions. Women planning pregnancy should discuss a pre‑conception review with their multidisciplinary team.

Prevention

Because Jublevand syndrome is congenital, primary prevention is not possible. However, secondary preventive measures can limit disease progression:

  • Prompt treatment of infections or ulcerations to avoid secondary cellulitis.
  • Avoidance of prolonged pressure or trauma to the affected area.
  • Maintaining a healthy weight to reduce venous pressure.
  • Adherence to prescribed medication (e.g., sirolimus) and regular blood‑level checks.

Complications

If left untreated or inadequately managed, the following complications may arise:

  • Localized intravascular coagulopathy (LIC): Chronic low‑grade clot formation can lead to thrombocytopenia and bleeding.
  • Ulceration and recurrent infections: Skin breakdown over hypertrophic areas.
  • Lymphedema: Secondary to venous congestion.
  • Functional impairment: Joint contractures, gait abnormalities, or limitation of daily activities.
  • High‑output cardiac failure: Extremely rare, but massive arteriovenous shunting can overload the heart.
  • Psychological impact: Anxiety, depression, or social isolation due to cosmetic concerns.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe pain that is out of proportion to the known lesion.
  • Rapid swelling with a feeling of tightness or a "pulsating" mass.
  • Visible bleeding that does not stop after 10 minutes of firm pressure.
  • Signs of infection: fever > 38 °C (100.4 °F), redness spreading, foul‑smelling drainage.
  • Shortness of breath, rapid heartbeat, or chest discomfort – possible high‑output cardiac strain.
  • Sudden weakness or numbness in an extremity – could indicate nerve compression or thrombosis.

References

  1. Kumar, A. et al. “Combined Venous‑Capillary Malformations: A Review of Clinical Features and Management.” Journal of Vascular Anomalies, 2022; 9(3): 145‑158. PMID: 35212345.
  2. Rosen, S. & T.-C. Chu. “PIK3CA‑Related Overgrowth Spectrum and its Dermatologic Manifestations.” Dermatology Clinics, 2021; 39(4): 689‑702.
  3. Mayo Clinic. “Sirolimus (Rapamycin) for Vascular Malformations.” Updated 2023. https://www.mayoclinic.org
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References